After five successful years of anticancer drug discovery activities, the NCI will issue Request for Proposals (RFP) to identify centers to participate in the second version of the CBC.
Questions? Join a presolicitation teleconference:
August 5, 2015, 3:30 p.m. – 4:30 p.m. EDT
August 19, 2015, 4:00 p.m. – 5:00 p.m. EDT
Dial in number: 1 888-394-8197
Who: Researchers in academia, government, and industry. A list of highly ranked applications can be found Here.
What: Drug discovery and development projects focused on unmet needs that are not adequately addressed by the private sector. The NCI is committed to moving high-priority projects through to proof-of-concept clinical trials. For more information, visit About NExT.
What NExT is not: NExT is not a grant or contract mechanism. Rather, approved projects will be provided access to the Institute's drug discovery and preclinical and clinical development resources.
How: Entry into NExT can occur at any stage of the drug discovery or development pipeline, but depends on favorable review of the application's scientific merit. For more information, visit How to Apply. Approved discovery activities may be performed by the NCI Chemical Biology Consortium, the discovery component of NExT.
When: Submission Deadlines occur three times per year.
Where: Online submission of NExT Application.
Sponsors: NCI's Division of Cancer Treatment and Diagnosis and Center for Cancer Research.